Business
Repligen Reports Fourth Quarter and Full Year 2019 Financial Results
Reports quarterly revenue of $69.5 million, representing 34% year-over-year growth, and annual revenue of $270.2 million represents 39% year-over-year
About this update from Repligen Corporation
[{"type":"text","content":"Reports quarterly revenue of $69.5 million, representing 34% year-over-year growth, and annual revenue of $270.2 million represents 39% year-over-year growthOverall organic revenue growth was 21% for the fourth quarter and 33% for the year 2019 WALTHAM, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2019. Provided in this press release are financial highlights for the three - and twelve-month periods ended December 31, 2019, followed by our current financial guidance for the year 2020, and access information for today’s webcast and conference call.\n Tony J. Hunt, President and Chief Executive Officer said, “We are delighted with the way we finished off 2019 with 21% organic growth in the fourth quarter and 33% for the full year. Our Filtration and Chromatography franchises accelerated in 2019 as we expanded our market presence as customers scaled these technologies into late stage processes. We also captured greater share in gene therapy manufacturing where sales more than doubled in 2019 to 15% of total revenue. Strategically, our acquisition of C Technologies established an important new Process Analytics franchise that delivered over $16M in the first 7 months of ownership. We anticipate that 2020 will be another positive year for the company as we continue to bring on additional manufacturing capacity, launch exciting new products and deliver on strong organic growth and earnings to our shareholders.” Fourth Quarter 2019 Highlights Revenue increased by 34% year-over-year as reported (35% at constant currency), to $69.5 million Organic revenue growth was 21% GAAP fully diluted EPS was $0.07 compared to $0.12 for the fourth quarter of 2018 Adjusted (non-GAAP) fully diluted EPS increased to $0.20 compared to $0.19 for the fourth quarter of 2018 Full Year 2019 Highlights Revenue increased by 39% year-over-year (41% at constant currency), to $270.2 million Organic revenue growth was 33%GAAP fully diluted EPS increased to $0.44 compared to $0.37 for the year 2018 Adjusted (non-GAAP) fully diluted EPS increased to $1.07 compared to $0.66 for the year 2018 Financial Details for the Fourth Quarter and Full Year 2019 REVENUE Total revenue for the fourth quarter of ...